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Introduction 39
Epigenetic mechanisms, such as DNA methylation, are increasingly recognized as having an 40 important role in the regulation of gene expression in response to environmental influences. 41 They have also been implicated in the development of autoimmune conditions, with a recent 42 genome-wide association study showing that the majority of causal variants linked to 43 autoimmune diseases are non-coding, acting via mechanisms such as histone acetylation and 44 transcription of non-coding RNAs (Farh et al., 2015) . There is also evidence that such 45 mechanisms are implicated in the development of inflammatory bowel diseases (IBD) 46 (Stylianou 2013) . Genetic variation alone accounts for only approximately 25% of IBD 47 heritability (Franke et al., 2010) , consistent with the growing recognition of the importance of 48 epigenetic mechanisms in heredity (Jablonka and Raz 2009 ). The different incidence of IBD 49 in monozygotic twins is supporting evidence for the role of epigenetic mechanisms in the 50 development of colitis, as are the alterations in global and gene-specific DNA methylation 51 that have been detected in mucosal biopsies of IBD patients (Toyota et al., 2002 , Maeda et 52 al., 2006 and in a mouse model of colitis (Hahn et al., 2008) . 53
In a dextran sodium sulphate (DSS)-induced model of colitis, aberrant DNA methylation of 54 three CpG islands was observed in colon epithelial cells, with the methylation levels within 55 these regions being increased from 8 weeks after DSS treatment until the development of 56 colon cancers 7 weeks later (Katsurano et al., 2012) . Inflammation triggered by the DSS 57 treatment appeared to be responsible for induction of methylation (Katsurano et al., 2012) ; 58 this prompted the question of whether inflammation-associated changes in DNA methylation 59 may also occur in other models of colitis. 60
We have consistently observed changes in the expression of several key regulatory genes in 61 inflamed colon tissue of interleukin-10 gene-deficient (Il10 -/-) mice, which has been widely 62 used as a model of human IBD by our group and others (de Buhr et al., 2006, Barnett et al., 63 2010, Selhub et al., 2013) . These genes include signal transducer and activator of 64 transcription 1 (Stat1) and peroxisome proliferator-activated receptor alpha (Ppara) ( Table 1 ; 65 (Knoch et al., 2009 ). Although the genetics of IBD is complex, with 66 ninety nine published IBD susceptibility loci (Lees et al., 2011) , the STAT1 gene is, among 67 others, consistently associated with its occurrence in human populations. The PPARA gene is 68 not specifically linked with human IBD, however because we have consistently seen this 69 gene differentially expressed in the Il10 -/mouse model, we were interested to investigate 70 whether there might also be differential DNA methylation within this gene. 71 STAT1 is a member of the signal transducer and activator of transcription (STAT) family of 72 transcription factor proteins (Xi et al., 2006) . STAT1 can be activated by various ligands, 73
including the inflammation-associated cytokines IFNγ and IL6, and mediates the expression 74 of a variety of genes important for cell viability in response to different cell stimuli and 75 pathogens. STAT1 protein activation and expression is increased in the intestinal mucosa in 76 IBD, although more so in Crohn's disease (CD) than in ulcerative colitis (UC) (Schreiber et 77 al., 2002) . Furthermore, a genome-wide association study has shown that STAT1 is one of 78 several genes differentially expressed in human CD samples compared to those from healthy 79 controls (Wu et al., 2007) . Changes in methylation patterns of the STAT1 gene have been 80 observed in several studies, for example methylation within the STAT1 gene promoter has 81 been linked to silencing of STAT1 gene expression in human squamous cell carcinoma of the 82 head and neck (Xi et al., 2006) . Furthermore, there is evidence of induction of Stat1 in 83 response to the DNA demethylating drug 5-aza-2'-deoxycytidine in a mouse model of 84 pancreatic carcinoma (Shakya et al., 2013) . This suggests that DNA methylation is one 85 mechanism by which Stat1 expression may be influenced. 86
PPARα is a member of the nuclear hormone receptor group of transcription factors which, 87 through negative regulation of inflammatory cytokine expression, plays an important role in 88 the immune response (Delerive et al., 1999 , Zhao et al., 2011 . Evidence suggests that 89 expression of the PPARA gene is linked to changes in DNA methylation within this gene. For 90 example, methylation at an intergenic CpG island 50 kb upstream of Ppara is associated with 91
decreased Ppara gene expression in mice (Carone et al., 2010) . Furthermore, increased 92
Ppara mRNA expression is associated with decreased CpG methylation in the Ppara 93 promoter in the liver of mice (Lillycrop et al., 2005) . Alterations in methylation state and 94 mRNA levels of Ppara may thus be interdependent, and may be modulated by colitis. 95
The putative role of the STAT1 gene in the pathogenesis of IBD, our consistent observation of 96 changes of Stat1 and Ppara expression associated with inflammation in Il10 -/mice, and the 97 potential for the expression of both genes to be linked to changes in DNA methylation, 98 suggested our hypothesis: that changes observed in the expression of Stat1 and Ppara in 99 colon tissue of Il10 -/mice are associated with differential methylation of CpG sites within 100 key regulatory regions of these genes. This hypothesis was investigated by measuring the 101 methylation levels of selected regions of the Stat1 and Ppara genes in C57BL/6J and Il10 -/-102 mice at six (prior to inflammation) and twelve (established inflammation, (Knoch et al., 103 2010)) weeks of age, using matrix-assisted laser deionisation, time of flight (MALDI-TOF) 104 mass spectrometry. 105
Materials and Methods 106
Ethics statement. The mouse experiment described in this paper was approved by the 107
AgResearch Limited (Ruakura) Animal Ethics Committee (application 11343), and was 108 carried out in strict accordance with the New Zealand Animal Welfare Act 1999. All efforts 109
were made to minimize suffering, and the animals were observed daily to identify possible 110 adverse effects on their health. 111
Animals, diet and breeding. Nineteen Il10 -/mice (Institute for Laboratory Animal Research 112 designation B6.129P2-Il10<tm1Cgn>/J) on a C57BL/6J genetic background were purchased 113 from the Jackson Laboratory (Maine, USA). Sixteen control C57BL/6JArc mice were 114 obtained from the AgResearch Ruakura Small Animal Colony (Hamilton, New Zealand). 115
Animals were kept under conventional conditions at a temperature of 22 °C, humidity of 116 60%, air exchange of 12 times/hour and with a 12 hour light/dark cycle. All mice had ad 117 libitum access to water, which was refreshed twice a week. 118
All mice were fed a non-sterile powdered AIN-76A diet (1977) which was made in-house at 119
Plant & Food Research, Palmerston North as previously described (Dommels et al., 2007) . 120
Experimental design. Following a 7 day stand-down period to allow the Il10 -/mice to 121 acclimatize following transportation, mice were randomly assigned to one of the following 122 sampling groups: pre-inflammation (6 weeks; Il10 -/mice n=9, C57 mice n=8) or post-123 inflammation (12 weeks; Il10 -/mice n=10, C5L/6JArc mice n=8). These times were based 124 on previous data from this mouse model which showed little evidence of 125 inflammation prior to 7 weeks of age, and peak inflammation occurring between 10 and 12 126 weeks of age. Once mice had been assigned to groups and transferred to individual cages, all 127 animals received a single oral inoculation of intestinal bacteria (Enterococcus species (10 6 ) 128 and complex intestinal flora derived from normal C57BL/6JArc mice, total volume 200 µL) 129
as has been previously applied in this mouse model (Knoch et al., 2009 . 130
Sample collection. At 6 or 12 weeks of age, samples were collected from mice as previously 131
described (Russ et al., 2013) . Briefly, mice were euthanized using CO 2 asphyxiation 132 followed by cervical dislocation . The intestine was quickly removed, cut open lengthwise and  133 flushed with 0.9% sodium chloride to remove any traces of digesta. Sections of each 134
intestinal region (duodenum, jejunum, ileum and colon) were then taken and frozen in liquid 135 nitrogen before storage at -85 °C for gene profiling (which has already been reported ( As shown in Figure 1 , no significant differences were observed (either with respect to time or 179 genotype) in the methylation of CpG sites within the analysed regions of Ppara. As shown in 180
Figure 2, no significant differences were observed (either with respect to time or genotype) in 181 the methylation of CpG sites within the proximal promoter region of Stat1. However, the 182 targeted region within intron 2 showed an overall reduction of methylation in Il10 -/mice at 183 12 weeks of age compared to C57 mice at 12 weeks of age (P < 0.001). Specifically, a 184 significant reduction in percentage methylation was observed at CpGs 1 (Il10 -/-: 10 ± 5% vs. 185
C57: 30 ± 5%, P < 0.001), 4-5 (Il10 -/-: 30 ± 9% vs. C57: 44 ± 4%, P < 0.01) and 12 (Il10 -/-: 186 18 ± 13% vs. C57: 37 ± 6%, P < 0.01) within this region. The apparent reduction in 187 methylation when comparing 12 week old Il10 -/mice with 6 week old mice of the same 188 genotype was not significant (P = 0.21). 189
Discussion 190
In this study, we observed a reduction in methylation levels in three CpG sites within intron 2 191 of the Stat1 gene. As shown in Table 1 . This is further evidence that altered DNA methylation within the 236 STAT1 gene may have a role in inflammation, and potentially supports the suggestion that our 237 observed increase of Stat1 gene expression in the Il10 -/mouse model may reflect the 238 involvement of this gene in the anti-inflammatory response. However, it must be noted that 239 the observed STAT1 hypomethylation in Sjogren's syndrome was on the promoter, not in 240 intron 2 as we have observed here. 241
Although methylation changes were found within the intron 2 region of Stat1 in this study, no 242 change in methylation levels was found for the promoter region of Stat1. Nor was there any 243 evidence of altered DNA methylation in the Ppara gene. Unfortunately it was beyond the 244 scope of this exploratory study to assess methylation at all CpG sites within these genes. 245
Other methods of assessing DNA methylation, such as bisulfite conversion or methyl- were obtained from the Jackson laboratory, whereas the C57BL/6JArc controls were obtained 254 from AgResearch Ruakura small animal facility (although these mice were originally derived 255 from the Jackson laboratory). It is well known that there can be wide variances in the 256 different C57BL/6 lines (Bryant et al., 2008 , Zurita et al., 2011 , Simon et al., 2013 . We do 257 not have any data to estimate the degree of such variation in this instance, and although both 258 strains are originally from the Jackson laboratory (Zurita et al., 2011) , we cannot exclude the 259 possibility that the methylation differences are due to genetic variation between the mouse 260 strains, rather than to either the Il10 -/mutation, or inflammation, per se. Using wild-type 261 littermates as controls for the Il10 -/mice in a future study would enable this point to be 262 clarified. 263
Because DNA was obtained from intact colon tissue in this study, it is possible that the 264 composition of different cell types within the samples analysed differed between the groups. 265
If this were the case, differences in DNA methylation could simply be due to these 266 differences in cell type. While we are unable to categorically rule this possibility out, we have 267 also undertaken genome-wide gene expression analysis in colon epithelial cells obtained from 268 the mice used in this study (Russ et al., 2013) . These results have shown differences in 269 expression of both Stat1 and Ppara mRNA in epithelial cells which are consistent with those 270 observed in intact colon tissue, and we therefore suggest that the differences in methylation 271
are also likely to be consistent. Measuring methylation of the target genes in epithelial cells 272 was beyond the scope of the current study, but is of interest for future studies. 273
In summary, to the best of our knowledge we have shown for the first time changes in DNA 274 methylation within the Stat1 gene in colon tissue from the Il10 -/mouse model of IBD, which 275 may be linked to the inflammation observed in this model. Epigenetic mechanisms act 276 upstream of transcription and identifying their involvement in the inflammatory process and 277 its regulation is an important step in gaining further insight into the pathogenesis of 278 autoimmune diseases such as IBD. Many studies have described gene expression profiles in 279 IBD-affected tissues and mouse models of IBD. Further investigation of the epigenetic 280 changes in these tissues, particularly those which enable the identification of causal links 281 between these changes and the underlying phenotype, will improve understanding of how 282 these pathways are involved in the development of IBD, as well as providing insights into 283 potential therapeutic approaches to its treatment or prevention. 284
Supplementary Material 285
The level of methylation at each CpG island for individual mice is provided as 286
Supplementary File 1 (Microsoft Excel). 287
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